Hormonal Contraceptive Eligibility for Women at High HIV Risk

The Food and Drug Administration (FDA) has released draft guidance concerning the eligibility criteria for hormonal contraceptives for women who are at high risk of contracting HIV. This document, identified by FDA-2026-P-2641-0023, is intended to provide updated recommendations for healthcare providers and manufacturers on prescribing these contraceptives in light of current scientific understanding of HIV risk and prevention.

Healthcare providers and pharmaceutical manufacturers should review this draft guidance to understand the FDA's current thinking on the topic. The agency is seeking public comment on these recommendations, and regulated entities should be prepared to adapt their practices or product information based on the final guidance. While this is draft guidance and non-binding, it signals the FDA's direction and may influence future regulatory actions or clinical practice standards.